Qiagen

Global Oncology Molecular Diagnostics Market Report 2020-2030: Major Players are Abbott Diagnostics, BD, Cepheid, Danaher, Beckman Coulter, Leica Biosystems, Gen Probe, Qiagen, Roche, Siemens

Retrieved on: 
Wednesday, February 17, 2021
Companies, Organizations, Medical software, Qiagen, Cepheid, Molecular diagnostics, Danaher Corporation, Roche Diagnostics, Leica Biosystems, Beckman Coulter, Innogenetics

Major players in the oncology molecular diagnostics market are Abbott Diagnostics, Becton Dickinson, Cepheid, Danaher Corporation, Beckman Coulter, Leica Biosystems, Gen Probe (Hologic), Qiagen N.V., Roche Diagnostics, and Siemens Healthcare.

Key Points: 
  • Major players in the oncology molecular diagnostics market are Abbott Diagnostics, Becton Dickinson, Cepheid, Danaher Corporation, Beckman Coulter, Leica Biosystems, Gen Probe (Hologic), Qiagen N.V., Roche Diagnostics, and Siemens Healthcare.
  • The high cost of molecular diagnostic tests is a key factor hampering the growth of the oncology molecular diagnostics market.
  • Therefore, the high cost of molecular diagnostic tests is expected to hamper the growth of the oncology molecular diagnostics market.
  • Global Oncology Molecular Diagnostics Market, Segmentation By Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
    4.2.

Global Oncology Molecular Diagnostics Market Report 2020 - ResearchAndMarkets.com

Retrieved on: 
Monday, February 15, 2021
Health, Oncology, Companies, States of Germany, Medical software, Qiagen, Danaher Corporation, Cepheid, Leica Biosystems, Molecular diagnostics, Siemens Healthineers, Beckman Coulter, Roche Diagnostics

The "Oncology Molecular Diagnostics Global Market Report 2020-30: COVID-19 Growth and Change" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Oncology Molecular Diagnostics Global Market Report 2020-30: COVID-19 Growth and Change" report has been added to ResearchAndMarkets.com's offering.
  • Major players in the oncology molecular diagnostics market are Abbott Diagnostics, Becton Dickinson, Cepheid, Danaher Corporation, Beckman Coulter, Leica Biosystems, Gen Probe (Hologic), Qiagen N.V., Roche Diagnostics, and Siemens Healthcare.
  • The global oncology molecular diagnostics market is expected to decline from $5.58 billion in 2019 to $5.25 billion in 2020 at a compound annual growth rate (CAGR) of -5.81%.
  • The high cost of molecular diagnostic tests is a key factor hampering the growth of the oncology molecular diagnostics market.

Global Clinical In Vitro Diagnostic Medical Laboratory Services Market Report 2021: COVID Related Testing Growth, Genetic Based Testing Creates New Department and New Discipline

Retrieved on: 
Thursday, February 11, 2021
Companies, Life sciences, Burlington, North Carolina, LabCorp, Corning Inc., Qiagen, Quest Diagnostics, Medical laboratory, Agilent Technologies, VCA Animal Hospitals

Quest Diagnostics to Acquire U.S.

Key Points: 
  • Quest Diagnostics to Acquire U.S.
  • Laboratory Services Business of Oxford Immunotec
    Mars, Incorporated to Acquire VCA Inc.
    LabCorp to acquire clinical laboratories from Mount Sinai.
  • $550 Dock Turns a Smartphone into a Medical Lab.
  • LabCorp & Interpace Extend Deal, Boost Cancer Portfolio
    QIAGEN Enters into Agreement to Acquire STAT-Dx.

QIAGEN Beats Outlook for Fourth Quarter and Full-Year 2020, Reaffirms Expectations for Further Growth in 2021

Retrieved on: 
Tuesday, February 9, 2021
Science, Biotechnology, Research, Medical Supplies, Oncology, Health, Medical devices, Infectious diseases, Medical software, Qiagen, Cer, Companies

Net sales in the fourth quarter of 2020 rose 38% (+36% at constant exchange rates, CER) to $571.2 million, and faster than the outlook for at least 32% CER growth.

Key Points: 
  • Net sales in the fourth quarter of 2020 rose 38% (+36% at constant exchange rates, CER) to $571.2 million, and faster than the outlook for at least 32% CER growth.
  • Adjusted earnings per share (EPS) grew 42% to $0.68 ($0.68 CER) against the outlook for about $0.64-0.65 CER.
  • Net sales for full-year 2020 increased 23% (+23% CER) to $1.87 billion, and exceeded the outlook for about 22% CER sales growth.
  • QIAGEN is committed to remaining at the forefront of the fight against COVID while expanding our business for post-pandemic growth.

Global Clinical In Vitro Diagnostic Medical Laboratory Services Market Strategies & Trends Report 2021 with Q12021 Update of COVID-19 Impacts - ResearchAndMarkets.com

Retrieved on: 
Tuesday, February 9, 2021
Medical devices, Health, Companies, Life sciences, Burlington, North Carolina, LabCorp, Corning Inc., Qiagen, Quest Diagnostics, Medical laboratory, Agilent Technologies, VCA Animal Hospitals

Quest Diagnostics to Acquire U.S.

Key Points: 
  • Quest Diagnostics to Acquire U.S.
  • Laboratory Services Business of Oxford Immunotec
    Mars, Incorporated to Acquire VCA Inc.
    LabCorp to acquire clinical laboratories from Mount Sinai.
  • $550 Dock Turns a Smartphone into a Medical Lab.
  • LabCorp & Interpace Extend Deal, Boost Cancer Portfolio
    QIAGEN Enters into Agreement to Acquire STAT-Dx.

QIAGEN Adds dPCR Platform QIAcuity to Growing Portfolio of COVID-19 Testing Solutions for Wastewater and Mutation Testing

Retrieved on: 
Thursday, January 28, 2021
Biotechnology, Infectious diseases, Health, Science, Research, Laboratory techniques, Molecular biology, Branches of biology, Natural sciences, Science and technology, Amplifiers, Digital polymerase chain reaction, Qiagen, Coronavirus disease, Polymerase chain reaction, Wastewater-based epidemiology

QIAGEN today announced the addition of kits for wastewater testing to its growing portfolio of COVID-19 products.

Key Points: 
  • QIAGEN today announced the addition of kits for wastewater testing to its growing portfolio of COVID-19 products.
  • The new kits are designed for use on the uniquely fast and easy-to-use series of QIAcuity instruments based on digital polymerase chain reaction (dPCR) technology.
  • The precision of QIAcuity provides a valuable tool for use in testing wastewater for SARS-CoV-2.
  • Potentially, surveillance testing can reveal infection and mutation dynamics earlier than diagnostic testing, providing public-health officials with near-real-time information on disease prevalence.

QIAGEN N.V. to Report Fourth Quarter and Full-Year 2020 Results

Retrieved on: 
Tuesday, January 26, 2021
Biotechnology, Health, Genetics, Pharmaceutical, Clinical trials, Medical software, Qiagen, Life sciences, Biotechnology, Biology, Companies, Bioinformatics, Molecular diagnostics, Biomatrica

Our sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.

Key Points: 
  • Our sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.
  • Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights.
  • QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare) and Life Sciences (academia, pharma R&D, and industrial applications, primarily forensics).
  • As of September 30, 2020, QIAGEN employed more than 5,300 people in over 35 locations worldwide.

India Molecular Diagnostics Market Report 2020: Market Stood at an Estimated $920 Million in 2020 - 10 Year Analysis & Forecasts 2016-2026

Retrieved on: 
Tuesday, January 26, 2021
Medical software, Qiagen, Biotechnology, Life sciences, Companies, Molecular diagnostics, BioMérieux, Roche Diagnostics, Biology

The Indian Molecular Diagnostics Market stood at an estimated 920 million in FY 2020 and is projected to grow at a CAGR of around 10% until FY 2026, predominantly on account of rising cases of fatal and chronic diseases.

Key Points: 
  • The Indian Molecular Diagnostics Market stood at an estimated 920 million in FY 2020 and is projected to grow at a CAGR of around 10% until FY 2026, predominantly on account of rising cases of fatal and chronic diseases.
  • Moreover, spread of COVID-19 pandemic is expected to create more opportunities, which is anticipated to drive the market growth during the forecast period.
  • Furthermore, government initiatives of raising funds for the country's molecular department is also expected to positively influence the market in the coming years.
  • Major players operating in the Indian Molecular Diagnostics Market include Roche Diagnostics India Pvt Ltd, Abbott India Limited, Qiagen India Pvt Ltd, bioMerieux India, Becton Dickinson Private Limited, Biocartis, Bio-Techne India Private Limited, Danaher, Bio-Rad laboratories India Pvt.Ltd, Cleaver Scientific, etc.

India Molecular Diagnostics Market, Competition, Forecast & Opportunities, FY 2026 - ResearchAndMarkets.com

Retrieved on: 
Friday, January 22, 2021
Health, Biotechnology, Life sciences, Medical software, Qiagen, Companies, Medical tests, Biology, Molecular diagnostics, BioMérieux, BD

The "India Molecular Diagnostics Market By Application (Infectious Disease, Blood Screening, Genetic Testing, Oncology Testing), By Technology (PCR, In-situ Hybridization, Chips and Microarrays, Others), By End User, By Region, Competition, Forecast & Opportunities, FY 2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "India Molecular Diagnostics Market By Application (Infectious Disease, Blood Screening, Genetic Testing, Oncology Testing), By Technology (PCR, In-situ Hybridization, Chips and Microarrays, Others), By End User, By Region, Competition, Forecast & Opportunities, FY 2026" report has been added to ResearchAndMarkets.com's offering.
  • The Indian Molecular Diagnostics Market stood at an estimated $920 million in FY 2020 and is projected to grow at a CAGR of around 10% until FY 2026, predominantly on account of rising cases of fatal and chronic diseases.
  • Moreover, spread of COVID-19 pandemic is expected to create more opportunities, which is anticipated to drive the market growth during the forecast period.
  • Major players operating in the Indian Molecular Diagnostics Market include Roche Diagnostics India Pvt Ltd, Abbott India Limited, Qiagen India Pvt Ltd, bioMerieux India, Becton Dickinson Private Limited, Biocartis, Bio-Techne India Private Limited, Danaher, Bio-Rad laboratories India Pvt.Ltd, Cleaver Scientific, etc.

QIAGEN Confirms Effectiveness of Its SARS-CoV-2 PCR Tests in the Face of Mutations of the Coronavirus

Retrieved on: 
Wednesday, January 20, 2021
Health, Infectious diseases, Genetics, Research, Science, Biotechnology, Sarbecovirus, Nidovirales, Zoonoses, Animal diseases, Severe acute respiratory syndrome coronavirus 2, GISAID, Severe acute respiratory syndrome coronavirus, Qiagen, Severe acute respiratory syndrome, Severe acute respiratory syndrome–related coronavirus

QIAGEN has successfully assessed its SARS-CoV-2 PCR tests against genetic mutations of the virus uploaded to the GISAID and GenBank public databases since May 2020.

Key Points: 
  • QIAGEN has successfully assessed its SARS-CoV-2 PCR tests against genetic mutations of the virus uploaded to the GISAID and GenBank public databases since May 2020.
  • A latest round of assessments conducted in January 2021 again confirmed that no recorded mutations affected the sensitivity of QIAGEN assays for detection of SARS-CoV-2.
  • As a virus encoded by RNA nucleotides, SARS-CoV-2 frequently mutates due to erroneous or ineffective replication of the virus genome.
  • These mutations can sometimes produce viruses with altered properties or even entirely new strains.